Abstract
Treatment of advanced pancreatic cancer has not improved substantially in recent years. The search for new agents or new therapeutic modalities may be critical for further development in the therapy of this disease. Experimental and clinical findings suggest that it might be possible to develop a new hormonal therapy for exocrine cancer of the pancreas based on new somatostatin analogues. Preliminary results indicate clinical activity and increased survival in some patients. In this study, 19 patients with advanced exocrine pancreatic carcinoma were given the somatostatin analogue BIM 23014 using a range of doses from 250 μg/day to 1 mg/day. One patient had a partial response, 6 patients had stable disease, and 11 had progressive disease. Six patients showed a sharp improvement in pain and performance status. Side effects were mild. Plasma levels of growth hormone were evaluated in ten patients and remained unchanged. The clinical activity observed, even if limited, warrants further investigation using more appropriate schedules and administration techniques.
| Original language | English |
|---|---|
| Pages (from-to) | 648-650 |
| Number of pages | 3 |
| Journal | Cancer |
| Volume | 69 |
| Issue number | 3 |
| Publication status | Published - 1992 |
Fingerprint
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Treatment of advanced pancreatic carcinoma with the somatostatin analogue BIM 23014. Preliminary results of a pilot study. / Canobbio, L.; Boccardo, F.; Cannata, D.; Gallotti, P.; Epis, R.
In: Cancer, Vol. 69, No. 3, 1992, p. 648-650.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Treatment of advanced pancreatic carcinoma with the somatostatin analogue BIM 23014. Preliminary results of a pilot study
AU - Canobbio, L.
AU - Boccardo, F.
AU - Cannata, D.
AU - Gallotti, P.
AU - Epis, R.
PY - 1992
Y1 - 1992
N2 - Treatment of advanced pancreatic cancer has not improved substantially in recent years. The search for new agents or new therapeutic modalities may be critical for further development in the therapy of this disease. Experimental and clinical findings suggest that it might be possible to develop a new hormonal therapy for exocrine cancer of the pancreas based on new somatostatin analogues. Preliminary results indicate clinical activity and increased survival in some patients. In this study, 19 patients with advanced exocrine pancreatic carcinoma were given the somatostatin analogue BIM 23014 using a range of doses from 250 μg/day to 1 mg/day. One patient had a partial response, 6 patients had stable disease, and 11 had progressive disease. Six patients showed a sharp improvement in pain and performance status. Side effects were mild. Plasma levels of growth hormone were evaluated in ten patients and remained unchanged. The clinical activity observed, even if limited, warrants further investigation using more appropriate schedules and administration techniques.
AB - Treatment of advanced pancreatic cancer has not improved substantially in recent years. The search for new agents or new therapeutic modalities may be critical for further development in the therapy of this disease. Experimental and clinical findings suggest that it might be possible to develop a new hormonal therapy for exocrine cancer of the pancreas based on new somatostatin analogues. Preliminary results indicate clinical activity and increased survival in some patients. In this study, 19 patients with advanced exocrine pancreatic carcinoma were given the somatostatin analogue BIM 23014 using a range of doses from 250 μg/day to 1 mg/day. One patient had a partial response, 6 patients had stable disease, and 11 had progressive disease. Six patients showed a sharp improvement in pain and performance status. Side effects were mild. Plasma levels of growth hormone were evaluated in ten patients and remained unchanged. The clinical activity observed, even if limited, warrants further investigation using more appropriate schedules and administration techniques.
UR - http://www.scopus.com/inward/record.url?scp=0026501635&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026501635&partnerID=8YFLogxK
M3 - Article
C2 - 1346097
AN - SCOPUS:0026501635
VL - 69
SP - 648
EP - 650
JO - Cancer
JF - Cancer
SN - 0008-543X
IS - 3
ER -